BRPI0923377A2 - Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos - Google Patents

Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos

Info

Publication number
BRPI0923377A2
BRPI0923377A2 BRPI0923377-6A BRPI0923377A BRPI0923377A2 BR PI0923377 A2 BRPI0923377 A2 BR PI0923377A2 BR PI0923377 A BRPI0923377 A BR PI0923377A BR PI0923377 A2 BRPI0923377 A2 BR PI0923377A2
Authority
BR
Brazil
Prior art keywords
treatment
mast cell
mediated diseases
cell mediated
aminoalkylcyclohexane derivatives
Prior art date
Application number
BRPI0923377-6A
Other languages
English (en)
Inventor
Hjalmar Kurzen
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0923377A2 publication Critical patent/BRPI0923377A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0923377-6A 2008-12-19 2009-12-18 Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos BRPI0923377A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20319408P 2008-12-19 2008-12-19
EP08022151 2008-12-19
PCT/EP2009/009151 WO2010069595A1 (en) 2008-12-19 2009-12-18 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases

Publications (1)

Publication Number Publication Date
BRPI0923377A2 true BRPI0923377A2 (pt) 2015-07-21

Family

ID=40547765

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923377-6A BRPI0923377A2 (pt) 2008-12-19 2009-12-18 Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos

Country Status (13)

Country Link
US (3) US8399519B2 (pt)
EP (1) EP2373304B1 (pt)
JP (1) JP5385402B2 (pt)
KR (1) KR101335118B1 (pt)
CN (1) CN102159201A (pt)
AU (1) AU2009328497A1 (pt)
BR (1) BRPI0923377A2 (pt)
CA (1) CA2737335C (pt)
IL (1) IL213607A0 (pt)
MX (1) MX2011006353A (pt)
RU (1) RU2484813C2 (pt)
WO (1) WO2010069595A1 (pt)
ZA (1) ZA201101789B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
JP5749261B2 (ja) * 2009-06-29 2015-07-15 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ３，３，５，５−テトラメチルシクロヘキサノンを調製する方法
CN103619354A (zh) * 2011-06-30 2014-03-05 东丽株式会社 止痒剂
DK3482771T3 (da) 2013-03-14 2023-03-20 Nestle Sa Fremstilling af jordnøddeformuleringer til oral desensibilisering
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
DK0724432T3 (da) 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
JPH10501238A (ja) 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション 肥満細胞媒介症状を治療するための組成物及び方法
CZ29799A3 (cs) * 1996-07-30 1999-06-16 Arris Pharmaceutical Corporation Disubstituovaná cyklická sloučenina, způsob její výroby, farmaceutický přípravek a způsob léčení onemocnění živočicha
EP0870757B1 (en) 1997-04-10 2002-06-12 Pfizer Inc. Fluoro-substituted adamantane derivatives
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
FR2768624B1 (fr) 1997-09-25 1999-11-12 Oreal Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
SE9801494D0 (sv) 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6345421B1 (en) 2000-05-12 2002-02-12 Milliken & Company Fabric treatment apparatus comprising easily removable, lightweight, treatment tubes
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2813189B1 (fr) 2000-08-31 2003-02-28 Oreal Creme cosmetique moussante pour le traitement des peaux grasses
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2005009421A2 (en) 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20050137122A1 (en) 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
JP2009526755A (ja) 2006-01-10 2009-07-23 ユー， リュイ ジェイ． Ｎ−（ホスホノアルキル）−アミノ酸、その誘導体及び組成物及びその利用法
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
WO2007117544A2 (en) * 2006-04-07 2007-10-18 Ssv Therapeutics, Inc. Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
DE102007003582A1 (de) 2007-01-24 2008-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Verwendung einer kosmetischen Zusammensetzung zur kosmetischen Behandlung der Haut
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類

Also Published As

Publication number Publication date
IL213607A0 (en) 2011-07-31
CN102159201A (zh) 2011-08-17
RU2484813C2 (ru) 2013-06-20
EP2373304B1 (en) 2014-07-30
KR20110074604A (ko) 2011-06-30
RU2011129830A (ru) 2013-01-27
KR101335118B1 (ko) 2013-12-05
JP2012510967A (ja) 2012-05-17
CA2737335C (en) 2013-10-01
MX2011006353A (es) 2011-07-13
CA2737335A1 (en) 2010-06-24
EP2373304A1 (en) 2011-10-12
US8680149B2 (en) 2014-03-25
US20130158124A1 (en) 2013-06-20
US20140107212A1 (en) 2014-04-17
US20110251283A1 (en) 2011-10-13
US8399519B2 (en) 2013-03-19
JP5385402B2 (ja) 2014-01-08
WO2010069595A1 (en) 2010-06-24
AU2009328497A1 (en) 2010-06-24
ZA201101789B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2329012T3 (da) Behandling af slagtilfælde under anvendelse af isolerede placentaceller
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
BR112012005594A2 (pt) tratamento de câncer
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0919020A8 (pt) terapia celular de tecido isquêmico
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0910534A2 (pt) terapia antiviral
BRPI0907950A2 (pt) Tratamento de hiperglicemia com 25-hidroxivitamina d3
BRPI0923377A2 (pt) Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
BR112012008959A2 (pt) tratamento de terapia de combinação para infecções virais
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI1007543A2 (pt) tratamento de psoríase
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida
GB0801888D0 (en) Treatment of mast cell related disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.